RecruitingPhase 2NCT05759572

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Apatinib in Combination With CDK4/6 Inhibitor and Endocrine Therapy as the First-line Therapy for HR+/ HER2-Advanced Breast Cancer

Sponsor

Fudan University

Enrollment

145 participants

Start Date

Feb 1, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Metastatic

Summary

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of apatinib (a drug that blocks blood vessel growth in tumors), a CDK4/6 inhibitor, and hormone therapy in women with advanced breast cancer that is hormone receptor-positive, HER2-negative, and belongs to the SNF-4 molecular subtype. **You may be eligible if...** - You are a female, 18–75 years old - You have advanced breast cancer that is hormone receptor-positive (ER/PR positive) and HER2-negative - Your cancer has been confirmed to be the SNF-4 molecular subtype - You have not previously been treated with a CDK4/6 inhibitor **You may NOT be eligible if...** - Your cancer is HER2-positive or hormone receptor-negative - You have brain metastases or cancer that has spread to the lining of the brain/spine - You have significant heart or blood vessel problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.